Mostrar o rexistro simple do ítem

dc.contributor.authorLasarte-Monterrubio, Cristina
dc.contributor.authorGuijarro, Paula
dc.contributor.authorBellés, Alba
dc.contributor.authorVázquez-Ucha, Juan Carlos
dc.contributor.authorArca-Suárez, Jorge
dc.contributor.authorFernández-Lozano, Carlos
dc.contributor.authorBou, Germán
dc.contributor.authorBeceiro, Alejandro
dc.date.accessioned2022-05-30T17:26:11Z
dc.date.available2022-05-30T17:26:11Z
dc.date.issued2022
dc.identifier.citationLASARTE-MONTERRUBIO, Cristina, et al. Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of bla OXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species. Microbiology spectrum, 2022, vol. 10, no 1, p. e02734-21 https://doi.org/10.1128/spectrum.02734-21es_ES
dc.identifier.urihttp://hdl.handle.net/2183/30820
dc.description.abstract[Abstract] Carbapenem resistance is increasing among Gram-negative bacteria, including the genus Acinetobacter. This study aimed to characterize, for the first time, the development of carbapenem resistance in clinical isolates of Acinetobacter junii and Acinetobacter nosocomialis conferred by the acquisition of a plasmid-borne blaOXA-24/40 gene and also to characterize the dissemination of this gene between species of Acinetobacter. Carbapenem-resistant A. nosocomialis HUAV-AN66 and A. junii HUAV-AJ77 strains were isolated in the Arnau de Vilanova Hospital (Spain). The genomes were sequenced, and in silico analysis were performed to characterize the genetic environment and the OXA-24/40 transmission mechanism. Antibiotic MICs were determined, and horizontal transfer assays were conducted to evaluate interspecies transmission of OXA-24/40. Carbapenems MICs obtained were ≥64 mg/L for HUAV-AN66 and HUAV-AJ77. Genome analysis revealed the presence in both strains of a new plasmid, designated pHUAV/OXA-24/40, harboring the carbapenem-resistance gene blaOXA-24/40 and flanked by sequences XerC/XerD. pHUAV/OXA-24/40 was successfully transferred from A. nosocomialis and A. junii to a carbapenem-susceptible A. baumannii strain, thus conferring carbapenem resistance. A second plasmid (pHUAV/AMG-R) was identified in both clinical isolates for the successful horizontal transfer of pHUAV/OXA-24/40. blaOXA-24/40-carrying plasmids of the GR12 group and showing high identity with pHUAV/OXA-24/40 were identified in at least 8 Acinetobacter species. In conclusion the carbapenemase OXA-24/40 is described for the first time in A. nosocomialis and A. junii. In both isolates the blaOXA-24/40 gene was located in the GR12 pHUAV/OXA-24/40 plasmid. GR12 plasmids are implicated in the dissemination and spread of carbapenem resistance among Acinetobacter species. IMPORTANCE Acinetobacter baumannii is one of the most relevant pathogens in terms of antibiotic resistance. The main resistance mechanisms are the carbapenem-hydrolyzing class D β-lactamases (CHDLs), especially OXA-23 and OXA-24/40. In addition to A. baumannii, there are other species within the genus Acinetobacter, which in general exhibit much lower resistance rates. In this work we characterize for the first time two clinical isolates of Acinetobacter nosocomialis and Acinetobacter junii, isolated in the same hospital, carrying the carbapenemase OXA-24/40 and displaying high resistance rates to carbapenems. By means of bioinformatics analysis we have also been able to characterize the mechanism by which this carbapenemase is horizontally transferred interspecies of Acinetobacter spp. The dissemination of carbapenemase OXA-24/40 between non-baumannii Acinetobacter species is concerning since it prevents the use of most β-lactam antibiotics in the fight against these resistant isolates.es_ES
dc.description.sponsorshipThis work was supported by Projects PI17/01482 and PI20/01212 awarded to A.B. and PI18/00501 to G.B., all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINF (CIBER de Enfermedades Infecciosas). The study was also funded by project IN607A 2020/05 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) awarded to G.B. and IN607D 2021/12 awarded to A.B. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J.A.-S.was financially supported by the Rio Hortega program (ISCIII, CM19/00219), J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and P.G.-S. was financially supported by IN607A 2020/05 Grant (Xunta de Galicia)es_ES
dc.description.sponsorshipXunta de Galicia; IN607A 2020/05es_ES
dc.description.sponsorshipXunta de Galicia; IN607D 2021/12es_ES
dc.description.sponsorshipXunta de Galicia; IN606A-2019/029es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiologyes_ES
dc.relationinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/PI17%2F01482/ES/EVALUACION DE NUEVAS ESTRATEGIAS ANTIMICROBIANAS MEDIANTE SILENCIAMIENTO DE ARN VEHICULIZADO EN NANOCAPSULAS E INHIBIDORES ENZIMATICOS/
dc.relationinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PI20%2F01212/ES/DESARROLLO Y EVALUACION DE NUEVAS MOLECULAS ANTIMICROBIANAS DIRIGIDAS A PATOGENOS MULTIRRESISTENTES (INHIBIDORES DE ß-LACTAMASAS Y CONJUGADOS TETRACICLINAS-SIDEROFOROS). ESTUDIO NACIONAL ACINETOBACTER SPP/
dc.relationinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PI18%2F00501/ES/DISEÑO Y DESARROLLO DE UNA VACUNA PARA LA PREVENCION Y ERRADICACION DE LAS INFECCIONES RESPIRATORIAS AGUDAS Y CRONICAS (FIBROSIS QUISTICA) CAUSADAS POR PSEUDOMONAS AERUGINOSA/
dc.relationinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/RD16%2F0016%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relationinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/CM19%2F00219/ES/
dc.relation.urihttps://doi.org/10.1128/spectrum.02734-21es_ES
dc.rightsAtribución 4.0 Internacionales_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCarbapenemase OXA-24/40es_ES
dc.subjectAcinetobacter juniies_ES
dc.subjectAcinetobacter nosocomialises_ES
dc.subjectAcinetobacter specieses_ES
dc.subjectCarbapenem resistancees_ES
dc.subjectHorizontal transferes_ES
dc.subjectXerC/XerD sequenceses_ES
dc.titleCarbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Specieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleMicrobiology Spectrumes_ES
UDC.volume10es_ES
UDC.issue1es_ES
UDC.startPagee02734-21es_ES
dc.identifier.doi10.1128/spectrum.02734-21


Ficheiros no ítem

Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem